BMO Capital Maintains Market Perform on Bristol-Myers Squibb, Maintains $48 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has maintained its Market Perform rating and $48 price target for Bristol-Myers Squibb, as stated by analyst Evan Seigerman.
September 23, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BMO Capital continues to rate Bristol-Myers Squibb as Market Perform with a $48 price target, indicating a neutral outlook.
The reaffirmation of the Market Perform rating and price target suggests that BMO Capital sees no immediate catalysts for significant price movement in Bristol-Myers Squibb's stock. This neutral stance implies stability in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100